Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 13Thoracic 4Gastrointestinal 3Dermatologic 3Gynecologic 2Breast 2

Conditions

Ovarian Neoplasms 14Uterine Cervical Neoplasms 6Carcinoma, Ovarian Epithelial 6Stomach Neoplasms 5Fallopian Tube Neoplasms 5Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasms 4Endometrial Neoplasms 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Vaginal Neoplasms 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2Peritoneal Neoplasms 2Melanoma 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Vulvar Neoplasms 1Urethral Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Penile Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Multiple Myeloma 1

Interventions

pembrolizumab 41Nivolumab 18atezolizumab 8Specimen Handling 7Docetaxel 7durvalumab 6Paclitaxel 6Magnetic Resonance Spectroscopy 6Ipilimumab 6Cyclophosphamide 6Carboplatin 6fludarabine 4avelumab 4Oxaliplatin 4Leucovorin 4Early Intervention, Educational 4Counseling 4Biopsy 4temsirolimus 3spartalizumab 3pazopanib 3olaparib 3lenvatinib 3cabozantinib 3aldesleukin 3Trastuzumab 3Taxes 3Sirolimus 3Psychiatric Rehabilitation 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Capecitabine × Gynecologic × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02009449 2024-11-15

IVY

Eli Lilly and Company

Phase 1 Completed
353 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡